Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives $6.34 Average PT from Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) have earned an average recommendation of "Hold" from the eleven ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $6.34.

A number of equities research analysts have recently weighed in on MRVI shares. Bank of America reduced their price target on shares of Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Baird R W downgraded shares of Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 26th. Morgan Stanley cut their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a report on Tuesday, March 25th. Stifel Nicolaus set a $5.00 target price on Maravai LifeSciences in a report on Friday, March 21st. Finally, UBS Group cut their price target on Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a research note on Friday, March 21st.

Maravai LifeSciences Price Performance

Shares of MRVI stock traded down $0.05 on Monday, hitting $2.06. 858,284 shares of the company's stock were exchanged, compared to its average volume of 2,362,436. Maravai LifeSciences has a 12 month low of $1.67 and a 12 month high of $11.56. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The company has a 50 day moving average of $2.54 and a 200 day moving average of $4.73. The stock has a market cap of $522.66 million, a P/E ratio of -1.25 and a beta of 0.18.

Insider Buying and Selling

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the company's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the sale, the general counsel now owns 167,618 shares in the company, valued at $843,118.54. This represents a 12.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.63% of the stock is owned by insiders.

Institutional Trading of Maravai LifeSciences

Several hedge funds have recently modified their holdings of MRVI. Alyeska Investment Group L.P. grew its holdings in Maravai LifeSciences by 145.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 5,329,420 shares of the company's stock worth $29,045,000 after purchasing an additional 3,161,072 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Maravai LifeSciences by 29.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,664,210 shares of the company's stock valued at $25,420,000 after buying an additional 1,062,485 shares during the period. JPMorgan Chase & Co. increased its position in Maravai LifeSciences by 4.9% in the 4th quarter. JPMorgan Chase & Co. now owns 4,250,656 shares of the company's stock valued at $23,166,000 after buying an additional 200,411 shares in the last quarter. Ameriprise Financial Inc. raised its stake in Maravai LifeSciences by 1.8% during the 4th quarter. Ameriprise Financial Inc. now owns 3,611,625 shares of the company's stock worth $19,683,000 after buying an additional 62,123 shares during the period. Finally, Jennison Associates LLC boosted its holdings in Maravai LifeSciences by 0.3% in the fourth quarter. Jennison Associates LLC now owns 2,990,414 shares of the company's stock worth $16,298,000 after acquiring an additional 9,769 shares in the last quarter. Institutional investors own 50.25% of the company's stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.